药明巨诺-B(02126)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02126 药明巨诺-B

未开盘 09-03 16:08:19

2.015

+0.045

+2.28%

最高2.040	最低1.970	成交量24.65万
今开1.970	昨收1.970	日振幅3.55%
总市值8.40亿	流通市值8.40亿	总股本4.17亿
成交额49.49万	换手率0.06%	流通股本4.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02126","market":"HK","secType":"STK","nameCN":"药明巨诺-B","latestPrice":2.015,"timestamp":1788422899138,"preClose":1.97,"halted":0,"volume":246500,"delay":0,"changeRate":0.022842639593908705,"floatShares":417000000,"shares":417000000,"eps":-1.5638778822256545,"marketStatus":"未开盘","change":0.045,"latestTime":"09-03 16:08:19","open":1.97,"high":2.04,"low":1.97,"amount":494945,"amplitude":0.035533,"askPrice":2.015,"askSize":15000,"bidPrice":2,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.947024924750488,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":0,"adr":0,"listingDate":1604332800000,"exchange":"SEHK","adjPreClose":1.97,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":0.159736,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02126","defaultTab":"news","newsList":[{"id":"1154562301","title":"药明巨诺-B更新2026年8月股份变动月报，总股本增至416,768,373股","url":"https://stock-news.laohu8.com/highlight/detail?id=1154562301","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154562301?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:02","pubTimestamp":1788429734,"startTime":"0","endTime":"0","summary":"药明巨诺-B于2026年9月3日发布截至2026年8月31日的股份变动月报。公告显示，公司法定股本维持5,000,000,000股普通股不变，面值每股0.00001美元，合计注册股本维持50,000美元。报告期内，药明巨诺-B已发行股份由上月期末的416,729,433股增至416,768,373股，新增38,940股，来源于2019年9月4日采纳的首次公开发售前激励计划，相关交易共带来3.89美元资金。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470825","title":"药明巨诺-B(02126.HK)发布中期业绩，期内亏损5042.6万元 同比减少81.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662470825?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:01","pubTimestamp":1787824864,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02126","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149905224","title":"港股直击｜创新药股股价齐扬，隔夜美股公司Moderna股价飙升14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149905224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149905224?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:39","pubTimestamp":1787708343,"startTime":"0","endTime":"0","summary":"港股创新药股股价齐扬，云顶新耀升 8%，康方生物升 7%，药明巨诺升 5%，荣昌生物升 4%。消息面上，隔夜美股生物技术公司莫德纳(Moderna)股价飙升14%，此前巴克莱上调了其目标价，且投资机构Wolfe Research也看好该公司mRNA癌症疫苗的商业潜力。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","01952","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184543711","title":"药明巨诺-B（02126）发布公告：董事会将于8月27日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1184543711","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184543711?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:36","pubTimestamp":1786523767,"startTime":"0","endTime":"0","summary":"8月12日，药明巨诺-B（02126）公告称，公司董事会已决定于2026年8月27日（星期四）召开董事会会议，主要议程包括：  \n1. 审议并批准本集团截至2026年6月30日止六个月的未经审计中期业绩及其发布；  \n2. 处理其他相关事宜。\n公告显示，药明巨诺-B现任董事会成员包括：执行董事兼主席田丰先生；非执行董事李怡平医生、高星女士；独立非执行董事何建昌先生、Debra Yu医生及陈炳钧先生。\n上述信息均来自公司于2026年8月12日在香港联交所发布的正式公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162361602","title":"药明巨诺-B2026年7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1162361602","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162361602?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:45","pubTimestamp":1785919553,"startTime":"0","endTime":"0","summary":"2026年8月5日，药明巨诺-B发布截至2026年7月31日止的证券变动月报。公告显示，公司全称为JW  Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司*，报告期内公司已发行和注册股本均保持稳定。公司披露，报告期末法定/注册股本总额为50,000美元，与上月持平。期末已发行股份总数为416,729,433股，库藏股份数量为零，与上月相比均无变化。报告期内，包括已授出的多项期权，未发生相应新股增发或库存股转让，也未新增因行使股权激励而导致的股份变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117263948","title":"药明巨诺-B6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1117263948","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117263948?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:47","pubTimestamp":1783327644,"startTime":"0","endTime":"0","summary":"2026年7月6日，药明巨诺-B发布截至2026年6月30日的股份变动月报表。公司注册股本仍为5,000,000,000股，面值每股0.00001美元，对应注册资本总额50,000美元。本月已发行股份总数维持在416,729,433股，库藏股为0，与上月保持一致。月报显示，公司未有任何新增发行、购回或注销股份活动，股本结构无重大变化。公告由执行董事田丰签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646635228","title":"药明巨诺-B(02126.HK)委任田丰为主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2646635228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646635228?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:13","pubTimestamp":1782475981,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106072163","title":"药明巨诺-B更新5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1106072163","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106072163?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:42","pubTimestamp":1780476173,"startTime":"0","endTime":"0","summary":"药明巨诺-B于2026年6月3日发布2026年5月股份变动月报表。公告显示，截至2026年5月31日，公司法定股本维持5,000,000,000股，面值均为每股0.00001美元，总额保持在50,000美元，与上月一致。公司已发行股份维持416,729,433股，与上月持平。当月无新增发行、购回或注销行为，也未产生库存股份变动。公告显示，该月报由公司执行董事田丰签署，并声明上述信息均遵守香港联交所《上市规则》及相关法律规定。截至报告期末，公司整体股本规模保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139256254","title":"药明巨诺-B拟回购不超过已发行股本10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1139256254","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139256254?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:36","pubTimestamp":1779784602,"startTime":"0","endTime":"0","summary":"药明巨诺（开曼）有限公司近日在公告中披露，董事会建议获得购回股份的一般授权，拟在股东大会通过相关决议后，于适用法律与香港联合交易所有限公司证券上市规则范围内，按不超过于决议案当日已发行股份数量10%的上限回购公司股份。根据公告，于最后可行日期，药明巨诺-B已发行并缴足股数为416,729,433股，若在股东大会前无新增股份发行或回购，最高可回购的数量为约41,672,943股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明巨诺-B拟回购不超过已发行股本10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636510428","title":"药明巨诺-B(02126)授出200万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2636510428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636510428?lang=zh_cn&edition=full","pubTime":"2026-05-19 21:30","pubTimestamp":1779197420,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明巨诺-B(02126)发布公告，于2026年5月19日，公司根据2020年10月14日采纳的公司首次公开发售后激励计划的条款将合共200万份购股权授予公司执行董事兼行政总裁田丰先生。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","BK1574","02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["81024","01833","02126","02197","00762","01060","02256","03888","06160","02306","06969","00719","01783","02158","01905","01024","01357","02192","02276","06996","02172","01951","06060","06186","01952","09626","06963","09858","00013","06660","09888","01548","02013","00169","02285","02171","09992","02096","02252","09688","02618","09699","00136","00909","06049","03692","06609","01440","00772","03700"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155206077","title":"药明巨诺-B4月股份变动月报表：已发行股份增至416,729,433股","url":"https://stock-news.laohu8.com/highlight/detail?id=1155206077","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155206077?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:47","pubTimestamp":1778143626,"startTime":"0","endTime":"0","summary":"JW  Therapeutics Co. Ltd于2026年5月7日披露截至2026年4月30日的证券变动月报。报告显示，公司本月完成若干股份增发，已发行股份由416,473,250股增加至416,729,433股，增幅为256,183股。截至2026年4月底，药明巨诺-B的已发行股份总数增至416,729,433股，公眾持股量继续符合香港联交所《上市规则》要求。公司确认所有证券发行及股份变动均已遵照相关法律法规及上市规则，所涉款项已足额收取，相关文件亦已在公司注册处按规定存档。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130623111","title":"药明巨诺-B 2025年度收入增至2.84亿元 毛利率提升至50.9% 研发聚焦带动亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1130623111","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130623111?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:08","pubTimestamp":1777334924,"startTime":"0","endTime":"0","summary":"在截至2025年12月31日止年度，药明巨诺-B实现收入人民币2.84亿元，较上一年度的人民币1.58亿元增长79.3%。公司整体毛利由上一年度的人民币7732万元增长至人民币1.73亿元，毛利率从48.9%进一步提升至50.9%，显示出产品销售与成本管控均有所加强。期内年内亏损为人民币5.55亿元，较上一年度的人民币5.91亿元收窄约6.0%。销售开支增长至人民币1.54亿元，一般及行政开支同比下降至人民币7849万元，研发开支则降至人民币1.88亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明巨诺-B 2025年度收入增至2.84亿元 毛利率提升至50.9% 研发聚焦带动亏损收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721894","title":"药明巨诺-B(02126)授出804万份购股权及22万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721894","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628721894?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:23","pubTimestamp":1776694998,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明巨诺-B(02126)发布公告，于2026年4月20日，公司根据2020年10月14日采纳的公司首次公开发售后激励计划的条款将合共804万份购股权;及根据2020年10月14日采纳的公司首次公开发售后受限制股份单位计划将合共22万个受限制股份单位授予公司30名承授人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163634740","title":"药明巨诺-B更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1163634740","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163634740?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:55","pubTimestamp":1775638552,"startTime":"0","endTime":"0","summary":"JW  Therapeutics Co. Ltd于2026年4月8日发布2026年3月股份变动月报表。报告显示，截至2026年3月31日，公司注册股本总额仍为5,000,000,000股，面值每股USD 0.00001，总额USD 50,000，较上月无变化。报告期内，公司已发行普通股为416,473,250股，与上月底持平，未发生新增发行、购回或注销等活动，库藏股数量维持在0股。根据公告信息，本报告由执行董事田丰签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622857005","title":"药明巨诺-B(02126)发布年度业绩 年内亏损5.55亿元 同比收窄5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857005","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622857005?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:29","pubTimestamp":1774528180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明巨诺-B(02126)发布截至2025年12月31日止年度业绩，该集团期内取得收入2.84亿元人民币，同比增加79.3%;年内亏损5.55亿元，同比收窄5.98%;每股基本亏损1.34元。该收入主要来自(i)集团目前处于商业化的产品倍诺达®的销售;及(ii)向Juno授予JW sLVV生产工艺及相关技术知识(以及专利)的非独家许可。产品收入由截至2024年12月31日止年度的人民币1.58亿元增加38.4%至截至2025年12月31日止年度的人民币2.19亿元。截至2025年12月31日止年度确认非独家许可收入人民币 6450万元，为报告期间的整体收入增长作出贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02126","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170225455","title":"药明巨诺-B：CAR-T疗法Carteyva作为R/R LBCL二线治疗的sNDA预计2026年获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1170225455","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170225455?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:25","pubTimestamp":1774527918,"startTime":"0","endTime":"0","summary":"药明巨诺-B（JW Therapeutics）宣布，其CAR-T细胞疗法Carteyva（relma-cel）作为复发或难治性大B细胞淋巴瘤（R/R LBCL）二线治疗的补充新药申请（sNDA），预计将于2026年获得中国国家药品监督管理局（NMPA）的批准。\n这一进展标志着Carteyva在拓展适应症方面取得重要突破。若获批，该疗法将为R/R LBCL患者提供新的治疗选择，进一步巩固药明巨诺在细胞治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618458149","title":"药明巨诺-B(02126.HK)3月26日举行董事会会议考虑及批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2618458149","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618458149?lang=zh_cn&edition=full","pubTime":"2026-03-11 18:07","pubTimestamp":1773223625,"startTime":"0","endTime":"0","summary":"格隆汇3月11日丨药明巨诺-B(02126.HK)宣布，公司谨订于2026年3月26日(星期四)举行董事会会议，藉以(其中包括)(i)考虑及批准集团截至2025年12月31日止年度之年度经审核综合业绩及其发布；(ii)建议之末期股息(如有)；以及(iii)处理任何其他事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260311/32060615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","BK1583","02126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618935191","title":"药明巨诺-B盘中异动 股价大涨5.26%报2.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618935191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618935191?lang=zh_cn&edition=full","pubTime":"2026-03-10 14:44","pubTimestamp":1773125050,"startTime":"0","endTime":"0","summary":"2026年03月10日下午盘14时44分，药明巨诺-B股票出现波动，股价大幅上涨5.26%。截至发稿，该股报2.000港元/股，成交量135.55万股，换手率0.33%，振幅5.26%。资金方面，该股资金流入120.418万港元，流出99.9115万港元。药明巨诺-B股票所在的生物技术行业中，整体涨幅为4.72%。其相关个股中，科济药业-B、加科思-B、三叶草生物-B涨幅较大，振幅较大的相关个股有云康集团、百奥赛图-B、三叶草生物-B，振幅分别为20.88%、18.26%、16.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310144410a45d9e87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310144410a45d9e87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02126","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518713228","title":"药明巨诺-B03月11日遭主力抛售17万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518713228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518713228?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:16","pubTimestamp":1741681001,"startTime":"0","endTime":"0","summary":"03月11日, 药明巨诺-B股价跌1.00%，报收1.98元，成交金额154万元，换手率0.19%，振幅5.00%，量比0.58。药明巨诺-B今日主力资金净流出17万元，连续4日净流出，上一交易日主力净流出43万元。该股近5个交易日上涨1.02%，主力资金累计净流出62万元；近20日主力资金累计净流入516万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311170058abf60a5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311170058abf60a5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","02126"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1044},{"period":"1month","weight":0.2438},{"period":"3month","weight":0.0495},{"period":"6month","weight":0.0495},{"period":"1year","weight":-0.6363},{"period":"ytd","weight":-0.1972}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明巨诺（开曼）有限公司是一家主要从事细胞免疫治疗产品的研究及开发、生产及上市的公司。该公司建立了一个细胞免疫治疗产品开发的一体化平台以及一条涵盖血液恶性肿瘤、实体瘤及自身免疫性疾病的产品管线。该公司的主要产品倍诺达是该公司在Juno（一家百时美施贵宝的公司）的嵌合抗原受体T细胞（CAR-T）细胞工艺平台的基础上，自主开发的一款靶向CD19的自体CAR-T细胞免疫治疗产品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01554},{"month":2,"riseRate":0.666667,"avgChangeRate":0.09316},{"month":3,"riseRate":0,"avgChangeRate":-0.160771},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.007666},{"month":5,"riseRate":0.5,"avgChangeRate":0.040085},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.012723},{"month":7,"riseRate":0.5,"avgChangeRate":0.077189},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.086516},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.063723},{"month":10,"riseRate":0.2,"avgChangeRate":-0.118018},{"month":11,"riseRate":0.4,"avgChangeRate":0.158609},{"month":12,"riseRate":0.5,"avgChangeRate":-0.061814}],"exchange":"SEHK","name":"药明巨诺-B","nameEN":"JW THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明巨诺-B(02126)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明巨诺-B(02126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明巨诺-B,02126,药明巨诺-B股票,药明巨诺-B股票老虎,药明巨诺-B股票老虎国际,药明巨诺-B行情,药明巨诺-B股票行情,药明巨诺-B股价,药明巨诺-B股市,药明巨诺-B股票价格,药明巨诺-B股票交易,药明巨诺-B股票购买,药明巨诺-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明巨诺-B(02126)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明巨诺-B(02126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}